Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-24 | Sarah Boyce 48 2019 President and CEO of Avidity Biosciences, Inc. ... Ms. Boyce’s executive experience in the biopharmaceutical industry and knowledge of our business contributed to our board of directors’ conclusion that she should serve as a director of our company. ... As of December 31, 2019, Ms. Boyce held options to purchase 5,283 shares of our common stock and 1,431 restricted stock units. During 2019, Ms. Boyce received 1,431 restricted stock units with a grant date fair value of $154,276 and 5,283 stock options with a grant date fair value of $270,103. ... Sarah Boyce 33,354 154,276 270,103 457,733 |
| 2020-11-12 | The following table provides information related to the compensation of each of our non-employee directors for fiscal 2019. Sarah Boyce Cash Fees $33,354, Stock Awards $154,276, Option Awards $270,103, Total $457,733 |
| 2021-04-23 | Sarah Boyce has served as a member of our board of director since October 2019. Since October 2019, Ms. Boyce has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics, a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms. Boyce served as Chief Business Officer at Ionis Pharmaceuticals from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms. Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG, Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also currently serves on the Board of Directors of Berkeley Lights Inc., a publicly-held biopharmaceutical company. Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England. Ms. Boyce’s executive experience in the biopharmaceutical industry and knowledge of our business contributed to our board of directors’ conclusion that she should serve as a director of our company. |
| 2022-04-22 | Sarah Boyce has served as a member of our board of directors since October 2019. Ms. Boyce is President and CEO of Avidity Biosciences, Inc. She also currently serves on the Board of Directors of Berkeley Lights Inc. Ms. Boyce’s executive experience in the biopharmaceutical industry and knowledge of our business contributed to our board of directors’ conclusion that she should serve as a director of our company. She is a member of the human capital management and compensation committee. Total compensation for 2021 was $320,307. |
Data sourced from SEC filings. Last updated: 2026-02-03